Jörg Westermann

TL;DR: The results suggest the BCAA–BCAT1–αKG pathway as a therapeutic target to compromise leukaemia stem-cell function in patients with IDHWTTET2WT AML.

TL;DR: A phase 2 hypothesis-generating trial to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls.

TL;DR: Serial measurable residual disease monitoring in bone marrow (BM) and peripheral blood (PB) samples of 155 intensively treated patients with RUNX1-RUNX1T1-positive AML and a refined practical guideline for MRD assessment is proposed.

TL;DR: This study analyzed all published cases since 1975 as well as cases from the authors' institution in order to present common clinical and molecular features of BCR-ABL+ AML and provides a clinical algorithm for the initial differential diagnosis of this rare disease.

TL;DR: Although the mechanism is still unclear, the high frequency of thyroid abnormalities, including autoimmune thyroiditis, warrants regular and long-term monitoring of thyroid function in patients with Ph-positive chronic myeloid leukemia.